Needham analyst Serge Belanger has maintained their bullish stance on NAMS stock, giving a Buy rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Serge Belanger has given his Buy rating due to a combination of factors surrounding NewAmsterdam Pharma Company’s strategic progress and financial stability. The company is actively advancing its clinical trials, including the PREVAIL CVOT and other significant studies like VINCENT and REMBRANDT. Additionally, the recent presentation of detailed phase 3 trial data from BROOKLYN, TANDEM, and BROADWAY at major medical meetings and publications underscores the company’s commitment to transparency and scientific rigor.
Furthermore, the anticipation of key data readouts, particularly from the PREVAIL CVOT expected in late 2026 or early 2027, positions the company for potential future growth. Financially, NewAmsterdam Pharma concluded the first quarter of 2025 with a robust cash position of approximately $805 million, which is projected to support operations well beyond the PREVAIL CVOT readout and into the initial stages of commercial launch. These factors collectively underpin the Buy rating, reflecting confidence in the company’s strategic direction and financial health.
According to TipRanks, Belanger is a 3-star analyst with an average return of 1.7% and a 41.54% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Cytokinetics, Esperion, and Evolus.